AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02510157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugammadex
Description: sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
Study NCT01929356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: 20 minutes of chest physiotherapy by physiotherapist
Study NCT04666441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN10933+REGN10987 combination therapy
Description: Administered IV or SC single dose
Study NCT04666441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered IV or SC single dose to match
Study NCT03460340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prefrontal deep rTMS of H1 Coil
Description: prefrontal deep rTMS of H1 Coil
Study NCT03460340 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: prefrontal deep rTMS of H1 Coil
Description: prefrontal deep rTMS of H1 Coil
Study NCT01117116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate and salmeterol
Description: 45/4.5 two puffs twice daily
Study NCT01117116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and formoterol
Description: 80/4.5 two puffs twice daily
Study NCT00461526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crofelemer
Description: 125 mg crofelemer vs. placebo
Study NCT04205045 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lactose Breath Test
Description: Lactose Breath Test is performed during the recruitment step. Fasting subjects are asked to ingest 20 g of lactose in a 10% water solution. Breath samples are collected at baseline and every 30 min after lactose ingestion, for an overall test duration of 4 h. A cut-off value of 20 ppm over the baseline will be used to identify lactose malabsorbers.
Study NCT04205045 — intervention group
Intervention type: OTHER
Intervention: Gut permeability test
Description: A 3-sugar probes test is conducted by administering 5 g lactulose, 2 g mannitol and 2 g sucralose in water solution to fasting subjects. Urine are collected at baseline (before sugar ingestion) and for time periods 0-5 h and 5-24 h.
Study NCT04205045 — intervention group
Intervention type: OTHER
Intervention: Milk Test
Description: Milk test will be performed by administering to fasting subjects a portion of 250 ml of semi-skimmed milk treated with ultra-high temperature (UHT). Glycaemia measurements, blood withdrawals and questionnaires completion will be performed at baseline and repeated after 30 minutes, 1, 2, 4 and 6 hours after milk ingestion. Urine collection will be performed at baseline and for 6 time intervals after milk ingestion (0-2, 2-4, 4-6, 6-8, 8-12, 12-24 hours).
Study NCT00079599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
Study NCT00461526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: crofelemer
Description: 125 mg crofelemer vs. placebo
Study NCT00079599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
Study NCT01732419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based training
Description: Home-based exercise training for cardiac patients.
Study NCT01732419 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Centre-based training
Description: Usual exercise training in an outpatient setting.
Study NCT03677102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: higher chloride crystalloid
Description: Normal saline (chloride concentration 154 mmol/L)
Study NCT03677102 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lower chloride crystalloid
Description: Ringer's Lactate (chloride concentration 110 mmol/L)
Study NCT03591328 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary CT angiography
Description: Comprehensive CCTA analysis of all culprit and non-culprit lesions to obtain their per-lesion and per-vessel quantitative, qualitative plaque, and hemodynamic features is performed by the independent core laboratory (HeartFlow, Mountain View, CA, USA) blinded to patient characteristics and ICA findings.~The current CCTA reporting variables, including % diameter stenosis, segment involvement score (SIS), and HRP features, are obtained for all lesions by another independent core laboratory (University of British Columbia, Vancouver, Canada) to construct a reference model. ICA and invasive imaging studies performed at the event of ACS are analyzed by the independent core laboratory (Samsung Medical Center, Seoul, Korea) to define the culprit lesion blinded to CCTA findings. Other independent experts match culprit and non-culprit lesion data between ICA and CCTA findings.
Study NCT01807845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: enriched skimmilk with VD
Description: enriched skimmilk with VD
Study NCT01807845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
Description: Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
Study NCT01807845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: un-enriched skimmilk.
Description: Placebo: un-enriched skimmilk
Study NCT02215447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAB paclitaxel
Description: 100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT02215447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00391521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS703569
Description: Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
Study NCT00391521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS703569
Description: Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
Study NCT00391521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AS703569
Description: Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
Study NCT02558322 — intervention group
Intervention type: OTHER
Intervention: Primary medical care
Description: All study participants receive primary care as usual in the respective region
Study NCT03330847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib Continuous (28-Day cycle) 300 mg BD.
Description: Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
Study NCT03330847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
Description: Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
Study NCT03330847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Description: Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
Study NCT02856620 — intervention group
Intervention type: OTHER
Intervention: Observational only
Description: Observational only
Study NCT00123110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
Study NCT00123110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide injection
Description: 3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
Study NCT00123110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill
Description: matching pill twice a day for 12 weeks
Study NCT00123110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: matching pill twice a day for 12 weeks
Study NCT00123110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo injection
Description: matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
Study NCT00123110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
Study NCT03455530 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Industrial Hygiene-Enhance Community Health Worker Intervention
Description: The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
Study NCT03455530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Industrial Hygiene-Enhance Community Health Worker Intervention
Description: The intervention will be derived from audits and exposure assessments and focus groups with workers and owners in the same business types (excluded from the trial) conducted in an earlier part of the study, as well as a community advisory group (e.g., Hispanic Chamber of Commerce) . From this, we will generate educational materials specific for each small business sector. We will provide the CHWs with a list of industry-specific control options along with potential cost savings and benefits. For example, EPA estimates a cost saving of $13,000 per year for auto body shops that switch to the high-velocity low-pressure spray guns. Each list will be a comprehensive menu of options that contain multiple control measures including simple controls, such as keeping the lids on the solvent containers.
Study NCT02426294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study NCT02426294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study NCT03722849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine Triphosphate
Description: Participants will inhale escalating concentrations of Adenosine Triphosphate (ATP) to induce cough and the urge-to-cough
Study NCT03722849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: Participants will inhale escalating concentrations of capsaicin to induce cough and the urge-to-cough
Study NCT03722849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Brain Imaging
Description: Participants will have scans of their brain activity using 3 Tesla (3T) brainstem restricted functional brain imaging (fMRI)
Study NCT03155061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4578
Description: ONO-4578 specified dose on specified days
Study NCT03155061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Description: ONO-4538 specified dose on specified days
Study NCT04253028 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NERv's Inline Device
Description: NERv's Inline Device attaches to existing catheters or peritoneal drains that are currently being used in the medical industry. This allows the device to measure the pH and conductance of intraperitoneal fluids that typically get drained through peritoneal drains.
Study NCT01995058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Tablets taken orally
Study NCT01995058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abiraterone
Description: Tablets taken orally daily
Study NCT01995058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Description: Tablets taken orally daily
Study NCT03383965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICAR30 T cells
Description: T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD30 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage.
Study NCT03717155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received avelumab intravenous infusions at a dose of 800 milligram (mg) on Day 1 and Day 8 of each 3-week cycle for the first 4 cycles. Thereafter, administered every 2 weeks in the Maintenance phase until disease progression or unacceptable toxicities.
Study NCT03717155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Participants received cetuximab intravenous infusions at a dose of 250 milligram per meter square (mg/m\^2) body surface area on Day 1 and 500 mg/m\^2 body surface area on Day 8 of first 4 cycles of concurrent chemotherapy. Thereafter, administered given at a dose of 500 mg/m\^2 intravenous every 2 weeks in the Maintenance phase, until disease progression or unacceptable toxicities.
Study NCT03717155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants received gemcitabine intravenous infusions at a dose of 1250 mg/m\^2 body surface area on Day 1 and Day 8 in 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
Study NCT03717155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Participants received cisplatin intravenous infusions at a dose of 75 mg/m\^2 body surface area on Day 1 of 3-week cycles up to a maximum of 4 cycles, until disease progression or unacceptable toxicities.
Study NCT03717155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: In case of cisplatin toxicities, participants were switched to carboplatin at a dose of target area under the serum concentration-time curve of 5 (AUC 5) on Day 1 for the remainder of cycles.
Study NCT02716961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, cisplatin
Description: Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
Study NCT01570790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 phosphate
Description: 27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
Study NCT01570790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate
Description: 36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
Study NCT01995058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Tablets taken orally twice daily
Study NCT01995058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Tablets taken orally twice daily
Study NCT03494816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib Oral Tablet
Description: Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities and blood pressure.~Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day with or without food as per instruction. On clinic days only, patients will be advised to fast for 6 hours prior to their clinic visit.~Patients should be advised to stop axitinib treatment a minimum of 36 hours and maximum of 7 days prior to week 9 nephrectomy and thrombectomy surgery.~Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol.
Study NCT04819282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Senior Fitness Test
Description: Senior Fitness Test, simple and easy to use, was used to evaluate physical performance.
Study NCT00203788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Description: Supported education/employment
Study NCT01570790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combretastatin A-4 Phosphate
Description: 45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
Study NCT03631706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received intravenous infusion of M7824 at a dose of 1200 milligrams (mg) once every 2 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Study NCT02795780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose
Study NCT02795780 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: positron emission tomography (PET) scan
Study NCT03568916 — intervention group
Intervention type: DRUG
Intervention: Apixaban (ATC B01AF02)
Description: Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Study NCT03568916 — intervention group
Intervention type: DRUG
Intervention: Dabigatran (ATC B01AE07)
Description: Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Study NCT03568916 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (ATC B01AF01)
Description: Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban at cohort entry date in patients diagnosed with non-valvular atrial fibrillation. Patients are considered exposed until end of follow-up regardless of switch or interruption.
Study NCT01900353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brushing methods
Study NCT03637270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplementation
Description: Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
Study NCT03637270 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation
Description: Before and after each exercise session, the research assistant will give subjects protein supplement or carbohydrate supplement according to the treatment assignment and ask them to drink it down right away.
Study NCT03637270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Including aerobic cycling training and progressive resisted exercise
Study NCT03637270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Including aerobic cycling training and progressive resisted exercise
Study NCT00203788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace Fundamentals Module
Description: Group skills training on job/school topics
Study NCT00203788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brokered Vocational Rehabilitation
Description: Vocational rehabilitation through traditional separate state-funded agency
Study NCT00203788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral risperidone
Description: Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
Study NCT00203788 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral risperidone
Description: Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
Study NCT00203788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Skills training group
Description: Group social skills training that did not focus primarily on work situations
Study NCT03631706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab: Participants received intravenous infusion of Pembrolizumab at a dose of 200 milligrams (mg) once every 3 weeks until confirmed progression of disease, death, unacceptable toxicity, or study withdrawal.
Study NCT02510443 — intervention group
Intervention type: DEVICE
Intervention: ESS305 (Essure, BAY1454032)
Description: Bilateral insert placement
Study NCT01656460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation Arm 1
Description: Dose Levels Dose per Fraction Total Dose~1 8 Gy 16 Gy
Study NCT01656460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation Arm 2
Description: Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
Study NCT01656460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation Arm 3
Description: Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy